A CCR5-Dependent Novel Mechanism for Type 1 HIV gp120 Induced Loss of Macrophage Cell Surface CD41
暂无分享,去创建一个
P. Simmonds | S. Howie | J. Logie | T. Hewson
[1] C. Broder,et al. Interactions of CCR5 and CXCR4 with CD4 and gp120 in human blood monocyte-derived dendritic cells. , 2000, Experimental and molecular pathology.
[2] S. Howie,et al. Interactions of HIV‐1 with antigen‐presenting cells , 1999, Immunology and cell biology.
[3] G. Trinchieri,et al. The interleukin-12-mediated pathway of immune events is dysfunctional in human immunodeficiency virus-infected individuals. , 1999, Blood.
[4] Q. Sattentau,et al. Constitutive cell surface association between CD4 and CCR5. , 1999, Proceedings of the National Academy of Sciences of the United States of America.
[5] James E. K. Hildreth,et al. T cell-tropic HIV gp120 mediates CD4 and CD8 cell chemotaxis through CXCR4 independent of CD4: implications for HIV pathogenesis. , 1999, Journal of immunology.
[6] D. Missé,et al. A CD4-independent interaction of human immunodeficiency virus-1 gp120 with CXCR4 induces their cointernalization, cell signaling, and T-cell chemotaxis. , 1999, Blood.
[7] D. Harrison,et al. A functional, discontinuous HIV‐1 gp120 C3/C4 domain‐derived, branched, synthetic peptide that binds to CD4 and inhibits MIP‐1α chemokine binding , 1999, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[8] S. Fidler,et al. Antigen presenting cell function in HIV-1 infected patients. , 1999, Immunology letters.
[9] T L Hoffman,et al. HIV-1 envelope determinants for cell tropism and chemokine receptor use. , 1999, Molecular membrane biology.
[10] H. Choe. Chemokine receptors in HIV-1 and SIV infection , 1998, Archives of pharmacal research.
[11] M. Zouali,et al. Selective deficit in antibodies specific for the superantigen binding site of gp120 in HIV infection , 1998, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[12] F. Peter. HIV nef: the mother of all evil? , 1998, Immunity.
[13] Ying Sun,et al. A conserved HIV gp120 glycoprotein structure involved in chemokine receptor binding. , 1998, Science.
[14] D. Gajdusek,et al. Adenovirus-mediated human immunodeficiency virus-1 Nef expression in human monocytes/macrophages and effect of Nef on downmodulation of Fcgamma receptors and expression of monokines. , 1998, Blood.
[15] A. Benner,et al. Anti-CD95 (APO-1/Fas) autoantibodies and T cell depletion in human immunodeficiency virus Type 1 (HIV-1)-infected children , 1998, Cell Death and Differentiation.
[16] V. Barnaba,et al. Autoimmune T-cell response to the CD4 molecule in HIV-infected patients. , 1998, Viral immunology.
[17] J. Hoxie,et al. Promonocytic U937 subclones expressing CD4 and CXCR4 are resistant to infection with and cell-to-cell fusion by T-cell-tropic human immunodeficiency virus type 1 , 1997, Journal of virology.
[18] L. Lopalco,et al. Human immunodeficiency virus type 1 glycoprotein 120-specific T lymphocytes provide intermolecular help for anti-CD4 autoantibody production in exposed uninfected subjects. , 1997, AIDS research and human retroviruses.
[19] O. Kutsch,et al. Rapid and selective depletion of CD4+ T lymphocytes and preferential loss of memory cells on interaction of mononuclear cells with HIV-1 glycoprotein-expressing cells. , 1997, Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association.
[20] N. Chirmule,et al. CD4 cross-linking (CD4XL) induces RAS activation and tumor necrosis factor-alpha secretion in CD4+ T cells. , 1997, Blood.
[21] H. Hashimoto,et al. Role of tumour necrosis factor‐alpha (TNF‐α) in the induction of HIV‐1 gp120‐mediated CD4+ T cell anergy , 1997, Clinical and experimental immunology.
[22] C. Pitcher,et al. CD4: a co-receptor in the immune response and HIV infection. , 1997, The international journal of biochemistry & cell biology.
[23] T. Coyle. Hematologic complications of human immunodeficiency virus infection and the acquired immunodeficiency syndrome. , 1997, The Medical clinics of North America.
[24] N. Ampel,et al. Analysis of autoantibodies to T-cell receptors among HIV-infected individuals: epitope analysis and time course. , 1997, Clinical immunology and immunopathology.
[25] Joseph Sodroski,et al. CD4-induced interaction of primary HIV-1 gp120 glycoproteins with the chemokine receptor CCR-5 , 1996, Nature.
[26] W. Cruikshank,et al. Interleukin 16 and its function as a CD4 ligand. , 1996, Immunology today.
[27] Newell,et al. Fas (CD95) expression and death-mediating function are induced by CD4 cross-linking on CD4+ T cells. , 1996, Proceedings of the National Academy of Sciences of the United States of America.
[28] G. Fine,et al. CD4 ligand IL-16 inhibits the mixed lymphocyte reaction. , 1996, Journal of immunology.
[29] N. Chirmule,et al. Envelope glycoproteins of human immunodeficiency virus type 1: profound influences on immune functions. , 1996, Microbiological reviews.
[30] V. Karsten,et al. HIV‐1 envelope glycoprotein gp120 down‐regulates CD4 expression in primary human macrophages through induction of endogenous tumour necrosis factor‐α , 1996, Immunology.
[31] L. Montaner,et al. Lipopolysaccharide (LPS) down‐regulates CD4 expression in primary human macrophages through induction of endogenous tumour necrosis factor (TNF) and IL‐1β , 1995, Clinical and experimental immunology.
[32] A. Smolyar,et al. Oligomerization of CD4 is required for stable binding to class II major histocompatibility complex proteins but not for interaction with human immunodeficiency virus gp120. , 1995, Proceedings of the National Academy of Sciences of the United States of America.
[33] I. Blanca,et al. Decreased T-cell proliferative response to common environmental antigens could be an indicator of early human immunodeficiency virus-mediated lymphocyte lesions , 1995, Clinical and diagnostic laboratory immunology.
[34] Fauci As. AIDS: newer concepts in the immunopathogenic mechanisms of human immunodeficiency virus disease. , 1995 .
[35] J. Sodroski,et al. Identification and characterization of monoclonal antibodies specific for polymorphic antigenic determinants within the V2 region of the human immunodeficiency virus type 1 envelope glycoprotein , 1995, Journal of virology.
[36] A. Fauci. AIDS: newer concepts in the immunopathogenic mechanisms of human immunodeficiency virus disease. , 1995, Proceedings of the Association of American Physicians.
[37] A. Theodore,et al. CD4 modulation of noninfected human T lymphocytes by HIV-1 envelope glycoprotein gp120: contribution to the immunosuppression seen in HIV-1 infection by induction of CD4 and CD3 unresponsiveness. , 1994, Journal of acquired immune deficiency syndromes.
[38] S. Rhee,et al. Human immunodeficiency virus type 1 Nef-induced down-modulation of CD4 is due to rapid internalization and degradation of surface CD4 , 1994, Journal of Virology.
[39] P. Ebbesen,et al. Antibody‐dependent enhancement of HIV‐1 infection in human term syncytiotrophoblast cells cultured in vitro , 1994, Clinical and experimental immunology.
[40] M. Ernst,et al. HIV‐1 envelope protein gp120 affects phenotype and function of monocytes in vitro , 1994, Journal of leukocyte biology.
[41] F. Belardelli,et al. Induction of beta interferon by human immunodeficiency virus type 1 and its gp120 protein in human monocytes-macrophages: role of beta interferon in restriction of virus replication , 1994, Journal of virology.
[42] M. Martin,et al. Human immunodeficiency virus type 1 Vpu protein induces rapid degradation of CD4 , 1992, Journal of virology.
[43] S. Levitz,et al. HIV-1 envelope protein (gp120) inhibits the activity of human bronchoalveolar macrophages against Cryptococcus neoformans. , 1992, The American review of respiratory disease.
[44] J. Goudsmit,et al. Minimal requirements for the human immunodeficiency virus type 1 V3 domain to support the syncytium-inducing phenotype: analysis by single amino acid substitution , 1992, Journal of virology.
[45] H. Schuitemaker,et al. Phenotype-associated sequence variation in the third variable domain of the human immunodeficiency virus type 1 gp120 molecule , 1992, Journal of virology.
[46] D. Littman,et al. The protein tyrosine kinase p56lck inhibits CD4 endocytosis by preventing entry of CD4 into coated pits , 1992, The Journal of cell biology.
[47] W. Cruikshank,et al. Identification of HIV‐1 Envelope Glycoprotein in the Serum of AIDS and ARC Patients , 1992, Journal of acquired immune deficiency syndromes.
[48] M. Waugh,et al. Regulation of human monocyte HLA-DR and CD4 antigen expression, and antigen presentation by 1,25-dihydroxyvitamin D3. , 1990, Blood.
[49] L. Arthur,et al. HIV-1 and its envelope glycoprotein down-regulate chemotactic ligand receptors and chemotactic function of peripheral blood monocytes. , 1989, Journal of immunology.
[50] M. Reitz,et al. Envelope sequences of two new United States HIV-1 isolates. , 1988, Virology.
[51] F. Barré-Sinoussi. HIV target cells: effect of their infection by HIV on the pathogenesis of AIDS. , 1988, Lymphology.
[52] Mark L. Pearson,et al. Complete nucleotide sequence of the AIDS virus, HTLV-III , 1985, Nature.